Adaptive Chemotherapy for Advanced Breast Cancer
Part of Cancer, Skin clinical trials.
This trial tests a new approach to chemotherapy that adapts over time for people with advanced breast cancer that has not responded to first-line treatment. It is designed to personalize treatment based on how the cancer responds, potentially improving outcomes with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced invasive breast cancer that has spread or cannot be removed by surgery.
- Your tumor type must be hormone receptor-positive/HER2-negative or triple-negative (HR-/HER2-).
- Your previous first-line treatment for metastatic disease has stopped working.
- If you are HR+/HER2-, you must have already tried endocrine therapy combined with a CDK4/6 inhibitor.
- If you have triple-negative breast cancer, you must have already tried chemotherapy with a PD-1 inhibitor (if PD-L1 CPS >= 1) or a PARP inhibitor (if you have a BRCA mutation).
- You have at least one measurable tumor as assessed by RECIST criteria and your overall health is good enough for study participation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment for advanced HER2-negative breast cancer. Doctors will take immune cells from lymph nodes near your tumor, grow them in a lab, and then give them back to you along with chemotherapy and immunotherapy. This approach aims to help your body fight the cancer more effectively.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This trial tests whether using a miniature version of your tumor grown in a lab can help choose the best treatment for advanced breast cancer. It compares this personalized approach to standard care.
This trial tests whether using a personalized approach—growing your tumor cells in the lab to find the best treatment—can work better than standard treatments chosen by your doctor. It is for people with advanced breast cancer that has stopped responding to at least two previous treatments.
This trial tests a new medicine that targets cancer cells with specific proteins, to see if it can stop the growth of advanced pancreatic and breast cancer when other treatments have stopped working. It is an umbrella study, which means different protein-matched drugs are tested for different cancer types.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.